STENTYS announced earnings results for the six months ended June 30, 2015. For the period, the company reported revenues of 2,606,000 against 1,936,000 a year ago. Operating loss was 5,449,000 against 13,339,000 a year ago.
Net loss was 5,421,000 against 13,190,000 a year ago, driven by a decrease in operating costs and the termination of the APPOSITION V clinical trial.